Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty
Notice bibliographique
Résumé
LettersOctober 1, 2013Aspirin Versus Low-Molecular-Weight Heparin After Total Hip ArthroplastySerena Granziera, MD and Alexander T. Cohen, MD, MBBS, MScSerena Granziera, MDFrom University of Padova, Padova, Italy; and King's College Hospital, London, United Kingdom.Search for more papers by this author and Alexander T. Cohen, MD, MBBS, MScFrom University of Padova, Padova, Italy; and King's College Hospital, London, United Kingdom.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-159-7-201310010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a multicenter randomized trial involving 786 patients having elective total hip replacement in Canada during a 3-year period, Anderson and colleagues (1) observed how, after 10 days of dalteparin therapy, 28 days of oral aspirin prophylaxis was noninferior to 28 days of dalteparin therapy for preventing venous thromboembolism (VTE). These results are very interesting to clinicians involved in elective hip surgery, particularly because some guidelines consider aspirin to be effective despite the single large randomized trial (2) quoted in the guidelines from the American College of Chest Physicians (3) that showed no effect of aspirin in ...References1. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158:800-6 LinkGoogle Scholar2. . Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-302. [PMID: 10776741] CrossrefMedlineGoogle Scholar3. Guyatt GH, Akl EA, Crowther M, Gutterman DD, and Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S. [PMID: 22315257] CrossrefMedlineGoogle Scholar4. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000;160:2208-15. [PMID: 10904465] CrossrefMedlineGoogle Scholar5. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75. [PMID: 18579811] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Padova, Padova, Italy; and King's College Hospital, London, United Kingdom.Disclosures: Dr. Cohen: Support for travel to meetings for the study or other purposes and fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like: Pfizer, Bristol-Myers Squibb; Board membership: Bayer, Bristol-Myers Squibb, Daiichi, Johnson & Johnson, Pfizer, Portola, Sanofi; Consultancy, payment for lectures including service on speakers bureaus, payment for development of educational presentations, travel/accommodations/meeting expenses unrelated to activities listed: Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi, Schering-Plough, Takeda; Other: Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi-Aventis, Schering-Plough, Takeda, U.K. Government All-Party Working Group on Thrombosis, U.K. Thromboprophylaxis Forum. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty David R. Anderson , Michael J. Dunbar , Eric R. Bohm , Etienne Belzile , Susan R. Kahn , David Zukor , William Fisher , Wade Gofton , Peter Gross , Stephane Pelet , Mark Crowther , Steven MacDonald , Paul Kim , Susan Pleasance , Nicki Davis , Pantelis Andreou , Philip Wells , Michael Kovacs , Marc A. Rodger , Tim Ramsay , Marc Carrier , and Pascal-Andre Vendittoli Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty David R. Anderson , Michael J. Dunbar , and Susan R. Kahn Metrics October 1, 2013Volume 159, Issue 7Page: 502KeywordsAnticoagulantsArthroplastyDeep vein thrombosisHemorrhageHipMedical risk factorsOrthopedicsProphylaxisPulmonary embolismSurgeryThoraxTotal hip replacementVenous thromboembolism ePublished: 1 October 2013 Issue Published: October 1, 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,002 | 0,014 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,001 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,001 | 0,000 |
| Intégrité de la recherche | 0,002 | 0,002 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,019 | 0,002 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».